NASDAQ: MEDP

Medpace (MEDP) Stock Analysis & Forecast

Nov 13 close

$653.94−2.90 (−0.4%)

Gekko Brief

AI summaryNov 9 close

Medpace's week centers on record Q3 2026 results, with revenue of $716 million up 8.5% year over year, EBITDA of $172.1 million rising 16%, and net income up 23.7% to $137.5 million. EPS came in at $4.84 against an estimate of $4.44, and the company posted all-time-high net new business awards of $873 million for the quarter, with last-12-month awards up 23.9% to $3.02 billion. The board also authorized a new $1 billion share repurchase program, and coverage this week has debated whether the stock is now fully valued following the beat and record backlog. A general counsel stock sale was also disclosed in a Form 4 filing during the period.

The stock closed at $672.93, up 3% on the day, and sits above both its 50-day average of $623.99 and its 200-day average of $530.79, with the 50-day above the 200-day. The GekkoIndex reads 54.2, placing it in the Neutral zone. Price stands 21.5% above Gekko Fair Value of $554.06, a sizable premium to that benchmark.

The next earnings date falls on 8 February 2027, outside a typical 20-day holding window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonally, the next 20 trading days have averaged a 3.6% decline over 5 years, with gains in only 1 of them, a pattern worth noting given the stock's recent run toward its 52-week high of $693.97.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Medpace price vs fair value

$653.94$546.25Nov ’25May ’26Nov ’26
Close $653.94200-day averageGekko Fair Value $546.25

Medpace quick facts

Market cap
$18.29B
P/E ratio
35.9
Forward P/E
33.3
EPS, TTM
$18.01
Revenue, TTM
$2.84B
Profit margin
18.2%
Dividend yield
—
Beta
1.11
Volume
105,446 avg 303,564
1-year return
+9.4%
Typical daily move
±3.1%
Typical 20-day move
±7%
50-day average
$629.52
200-day average
$532.01
Next earnings
Feb 8
Shares outstanding
27.97M
52-week range
$373.00$693.97

Medpace swing-trade checklist

Medpace scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive1 mixed2 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $653.94 is above the 50-day ($629.52) and 200-day ($532.01) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    57, Neutral

    Reading 57 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    19.7% above

    Price is 19.7% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 85 days

    Next report Feb 8, 2027, 85 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −2.9% on average

    From this point in the calendar, the next 20 trading days averaged −2.9% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Medpace stock chart and price history

Medpace closed at $653.94 on Nov 13, 2026, +9.4% over the past year, inside a 52-week range of $373.00 to $693.97.

Close50-day average200-day averageVolume
Medpace share price, past year, with 50-day and 200-day moving averages and volume$400$500$600$700DecJan 2026FebMarAprMayJunJulAugSepOctNov653.94

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+4.0%
3 months
+9.5%
6 months
+57.5%
1 year
+9.4%
The full MEDP chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MEDP in Gekko

Follow Medpace through every session

Put MEDP on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track MEDP in GekkoFree for 7 days. No credit card required.

About Medpace

Medpace provides contract research services that support the clinical development of new medical products. It works with pharmaceutical, biotechnology, and medical device companies, guiding studies from early Phase I testing through to post-market Phase IV surveillance. The company is recognized for covering this full span of drug and device development under one roof.

Its work spans designing trial programs, running central laboratory operations, managing projects and regulatory filings, overseeing clinical trials, and handling data management and pharmacovigilance. Medpace also assists clients with new drug application submissions and continued clinical monitoring after products reach the market. Beyond these core services, it operates bio-analytical laboratories, conducts human pharmacology studies, and offers imaging and ECG reading services used in clinical research. Its client base extends across North America, Europe, and Asia.

Medpace was founded in Cincinnati, Ohio, in 1992, where it remains based. Its shares are listed on the NASDAQ under the ticker MEDP.

Listed
NASDAQ
Sector
Commercial services
Industry
Miscellaneous commercial services
Website
medpace.com

Medpace GekkoIndex: the smart money zone

Medpace’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57, in the Neutral zone, up 0.9 points over five sessions.

010057Neutral

Up 0.9 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying28−0.1%+1.6%+1.0%+3.2%
Accumulation176+1.8%+1.9%+2.3%+1.9%
Neutral (current zone)440+0.6%+1.5%+2.7%+7.6%
Distribution51−0.8%+0.4%+8.3%+9.7%
Selling7Too few readings yet

Average MEDP share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the MEDP price, zone by zone.Track MEDP in Gekko

Is Medpace stock overvalued? Gekko Fair Value

Medpace trades 19.7% above Gekko Fair Value of $546.25, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Medpace shares are worth, recalculated every trading day.

$546.25

Gekko Fair Value, Nov 14, 2026

19.7% Overvalued

At the end of Aug 2026 the price was 15.6% above the estimate.

Gekko Fair ValueShare price, month end
$546$654Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open MEDP in Gekko

Medpace insider and Congress trading

No open-market insider purchases were filed for Medpace, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for MEDP in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every MEDP insider filing, plotted on the chart in Gekko.Open MEDP in Gekko

Congress trades last 90 days

No trades in MEDP were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for MEDP, plotted on the chart in Gekko.Open MEDP in Gekko

Buybacks

Medpace has been buying back its own shares.

Latest authorization
$1.00B, Oct 21, 2026
Bought back, quarter ended Jun 30, 2026
$294.8M
As a share of market cap
1.61%

From company filings.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds MEDP.

0added0opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Medpace earnings: next date and track record

Medpace reports on Feb 8, 2027 (85 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±16.9%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−7.4%Feb ’25−4.7%Apr ’25+53.2%Jul ’25+9.3%Oct ’25−17.7%Feb ’26−23.6%Apr ’26+13.9%Jul ’26+5.1%Oct ’26

Last earnings call, Oct 21, 2026 AI summary

What they said
Medpace reported Q3 2026 revenue of $716 million, up 8.5% YoY, with EBITDA of $172.1 million rising 16% and net income up 23.7% to $137.5 million. EPS was $4.84 vs $3.86 prior year. Net new business awards hit an all-time high of $873 million in Q3, with last-12-month awards up 23.9% to $3.02 billion. The board authorized a new $1 billion share repurchase program.
Guidance
Full year 2026 revenue guided to $2.835-$2.855 billion (12-12.8% growth), EBITDA of $638-$652 million (14.4-16.9% growth), and EPS of $17.97-$18.32. Management sees no significant disconnect between analyst 2027 consensus estimates and internal modeling.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 21, 2026$4.84
est $4.44
+9.0%$716.0M
est $714.5M
+0.2%+5.1%
Jul 22, 2026$4.25
est $3.98
+6.8%$707.3M
est $689.5M
+2.6%+13.9%
Apr 22, 2026$4.28
est $3.96
+8.1%$706.6M
est $697.6M
+1.3%−23.6%
Feb 9, 2026$4.67
est $4.19
+11.5%$708.5M
est $689.3M
+2.8%−17.7%
Oct 22, 2025$3.86
est $3.53
+9.3%$659.9M
est $641.0M
+2.9%+9.3%
Jul 21, 2025$3.10
est $2.98
+4.0%$603.3M
est $538.8M
+12.0%+53.2%
Apr 21, 2025$3.67
est $3.06
+19.9%$558.6M
est $526.3M
+6.1%−4.7%
Feb 10, 2025$3.68
est $3.12
+18.1%$536.6M
est $539.7M
−0.6%−7.4%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Medpace stock forecast and analyst price targets

Analysts’ average 12-month price target for Medpace is $651.31, −0.4% from the last close, from 9 firms rating the stock in the last 90 days.

$651.31consensus 12-month target, −0.4% from the last close
Low $560High $730
Buy3
Hold6
Sell0

Each firm’s latest rating in the last 90 days: 9 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Oct 26BMO CapitalHold, reiterated$670+2.5%
Oct 23UBSHold, reiterated$700+7.0%
Oct 23BarclaysHold, maintained$675+3.2%
Oct 23TD CowenHold, reiterated$673+2.9%
Oct 23Robert W. BairdBuy, maintained$699+6.9%
+2.7%average 20-day move after past Neutral readings
−2.9%average move over the next 20 trading days in the last 5 years
±3.1%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Medpace seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Medpace averaged −2.9% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−7.5%2021−2.9%2022+5.3%2023+3.3%2024−5.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.4%2 of 5
Next 10 trading days−4.4%0 of 5
Next 15 trading days−4.8%0 of 5
Next 20 trading days−2.9%1 of 5
Next 30 trading days−0.8%2 of 5

For scale, MEDP’s typical 20-trading-day move in either direction is about 7%.

Medpace market cap and key statistics

Medpace’s market cap is $18.29B, with a P/E ratio of 35.9 and revenue of $2.84B over the last twelve months.

Valuation

Market cap
$18.29B
P/E ratio
35.9
Forward P/E
33.3
EPS, TTM
$18.01
Gekko Fair Value
$546.25

Trading

Volume
105,446
Avg volume, 20 days
303,564
52-week high
$693.97
52-week low
$373.00
Shares outstanding
27.97M

Financials

Revenue, TTM
$2.84B
Profit margin
18.2%
Return on equity
117.9%
Quarterly earnings growth, YoY
+25.4%

Risk and income

Beta
1.11
Typical daily move
±3.1%
Typical 20-day move
±7%

Medpace stock news this week

Coverage of Medpace this week reads neutral: 2 positive, 4 neutral and 0 negative headlines.

News sentiment neutral

Medpace peers

Medpace’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
SHOPShopify−0.1%Accumulation0.6% above
CTASCintas−0.6%Neutral22.3% above
PYPLPayPal+1.1%Neutral5.3% above
XYZBlock+2.8%Neutral15.1% above
FISVFiserv+3.7%Distribution38.0% below
CPAYCorpay+0.6%Distribution5.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Miscellaneous commercial services

Medpace stock FAQ

What is Medpace’s market cap?

Medpace’s market cap is $18.29B at the Nov 13, 2026 close of $653.94, with 27.97M shares outstanding. The shares trade on a P/E ratio of 35.9.

What is the Medpace stock forecast?

The consensus analyst 12-month price target for Medpace is $651.31, −0.4% from the last close. Of the 9 firms that rated the stock in the last 90 days, 3 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Medpace stock overvalued or undervalued?

On Gekko’s estimate Medpace is overvalued: the Nov 13, 2026 close of $653.94 is 19.7% above Gekko Fair Value of $546.25. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Medpace report earnings next?

Medpace is expected to report on Feb 8, 2027 (85 days away). Analysts expect earnings of $4.82 per share on revenue of $718.4M. Medpace beat the earnings estimate in 8 of its last 8 reports, moving 16.9% on average across the report.

What is Medpace’s 52-week high and low?

Medpace’s 52-week high is $693.97 and its 52-week low is $373.00; it closed at $653.94 on Nov 13, 2026, +9.4% over the past year.

Is Medpace stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Medpace the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.